BRPI1013992A2 - composições e métodos para o tratamento de resistência à insulina e diabetes melito - Google Patents

composições e métodos para o tratamento de resistência à insulina e diabetes melito

Info

Publication number
BRPI1013992A2
BRPI1013992A2 BRPI1013992A BRPI1013992A BRPI1013992A2 BR PI1013992 A2 BRPI1013992 A2 BR PI1013992A2 BR PI1013992 A BRPI1013992 A BR PI1013992A BR PI1013992 A BRPI1013992 A BR PI1013992A BR PI1013992 A2 BRPI1013992 A2 BR PI1013992A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
diabetes mellitus
insulin resistance
treating insulin
Prior art date
Application number
BRPI1013992A
Other languages
English (en)
Portuguese (pt)
Inventor
Anthony B Wood
Gregory J Archambeau
Richard L Watson
Original Assignee
Revalesio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revalesio Corp filed Critical Revalesio Corp
Publication of BRPI1013992A2 publication Critical patent/BRPI1013992A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI1013992A 2009-04-27 2010-04-27 composições e métodos para o tratamento de resistência à insulina e diabetes melito BRPI1013992A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17313409P 2009-04-27 2009-04-27
PCT/US2010/032620 WO2010126908A1 (en) 2009-04-27 2010-04-27 Compositions and methods for treating insulin resistance and diabetes mellitus

Publications (1)

Publication Number Publication Date
BRPI1013992A2 true BRPI1013992A2 (pt) 2016-08-16

Family

ID=43032520

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013992A BRPI1013992A2 (pt) 2009-04-27 2010-04-27 composições e métodos para o tratamento de resistência à insulina e diabetes melito

Country Status (9)

Country Link
EP (1) EP2424507A4 (https=)
JP (2) JP2012525396A (https=)
CN (1) CN102413817B (https=)
AU (1) AU2010241736B2 (https=)
BR (1) BRPI1013992A2 (https=)
CA (1) CA2758738A1 (https=)
IL (1) IL215925A0 (https=)
MX (1) MX2011011333A (https=)
WO (1) WO2010126908A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US8399006B2 (en) 2009-01-29 2013-03-19 Forsight Vision4, Inc. Posterior segment drug delivery
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
JP6111194B2 (ja) 2010-08-05 2017-04-05 フォーサイト・ビジョン フォー・インコーポレーテッド 組み合わせ薬物送達方法および装置
SI2600812T1 (sl) 2010-08-05 2021-12-31 ForSight Vision4, Inc., Naprava za zdravljenje očesa
EP3861969A1 (en) 2010-08-05 2021-08-11 ForSight Vision4, Inc. Injector apparatus for drug delivery
JP2013533320A (ja) 2010-08-12 2013-08-22 レバレジオ コーポレイション タウオパチーを治療するための組成物および方法
AR083878A1 (es) * 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
ES2777890T3 (es) * 2010-11-15 2020-08-06 Boehringer Ingelheim Int Terapia antidiabética vasoprotectora y cardioprotectora
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US20120263764A1 (en) * 2011-04-13 2012-10-18 Revalesio Corporation Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease
EP4249059B1 (en) 2011-06-28 2025-07-30 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
RS61758B1 (sr) 2011-09-16 2021-05-31 Forsight Vision4 Inc Aparati za razmenu tečnosti
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
JP6159584B2 (ja) * 2012-06-14 2017-07-05 松本　高明 輸液、輸液の製造方法および輸液装置
CH706747A2 (de) * 2012-07-17 2014-01-31 Hanspeter Steffen Verfahren zur Hydration, Straffung und Pflege der Haut, zur Behandlung von Dermatosen, Sonnenbrand und genereller Wunden mit Diamantelektroden hergestelltem Elektrolysewasser.
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CA2905496A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
ES2972168T3 (es) 2013-03-28 2024-06-11 Forsight Vision4 Inc Implante oftálmico para administración de sustancias terapéuticas
WO2015099201A1 (ja) * 2013-12-27 2015-07-02 アクア・ゼスト株式会社 ナノバブル含有組成物およびその用途
US20170056438A1 (en) * 2014-10-17 2017-03-02 Aqua Zest Corporation Nanobubble-containing composition and use thereof
EP3169289B1 (en) 2014-07-15 2020-04-15 ForSight Vision4, Inc. Ocular implant delivery device
BR112017002466A2 (pt) 2014-08-08 2017-12-05 Forsight Vision4 Inc formulações estáveis e solúveis de inibidores da tirosina cinase do receptor, e métodos para a sua preparação
WO2016077371A1 (en) 2014-11-10 2016-05-19 Forsight Vision4, Inc. Expandable drug delivery devices and method of use
JP6674748B2 (ja) * 2015-05-27 2020-04-01 花王株式会社 Ｇｌｐ−１分泌促進剤
CA3005238A1 (en) 2015-11-20 2017-05-26 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
JP7009384B2 (ja) 2016-04-05 2022-01-25 フォーサイト・ビジョン フォー・インコーポレーテッド 移植可能な眼薬送達デバイス
CN105878194A (zh) * 2016-06-07 2016-08-24 沈阳药科大学 一种格列本脲纳米结晶制剂及其制备方法
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
CN106362166B (zh) * 2016-10-27 2019-12-10 武汉大学 肿瘤坏死因子受体相关泛支架和信号蛋白在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
KR20200093581A (ko) 2017-11-21 2020-08-05 포사이트 비젼4, 인크. 확장 가능한 포트 전달 시스템을 위한 유체 교환 기기 및 사용 방법
CN110006871A (zh) * 2019-02-20 2019-07-12 常州大学 一个基于外源性组胺检测的细胞模型以及应用
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005792A1 (de) * 1990-10-02 1992-04-16 Buchholz Klaus L Verwendung eines reaktionsproduktes aus einem gas und einer flüssigkeit, sowie verfahren und vorrichtung zu seiner herstellung
US7196164B2 (en) * 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
US6861227B2 (en) * 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
EP1357920B1 (en) * 2001-02-01 2007-09-05 Hydron Technologies Inc. Compositions and method of tissue superoxygenation
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
US20060273016A1 (en) * 2005-06-03 2006-12-07 BAGLEY David Method for preparing water with a stable negative oxidation reduction potential (ORP)
US8597689B2 (en) * 2006-10-25 2013-12-03 Revalesio Corporation Methods of wound care and treatment
AU2007308838B2 (en) * 2006-10-25 2014-03-13 Revalesio Corporation Mixing device and output fluids of same
US20080154795A1 (en) * 2006-12-25 2008-06-26 Amos Alon Auction platform and applications
JP2008156320A (ja) * 2006-12-26 2008-07-10 Hydrox Kk 抗酸化性機能水
US20090227018A1 (en) * 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
EP2215260A4 (en) * 2007-10-25 2011-04-20 Revalesio Corp COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION

Also Published As

Publication number Publication date
WO2010126908A1 (en) 2010-11-04
IL215925A0 (en) 2011-12-29
MX2011011333A (es) 2011-11-18
CN102413817B (zh) 2014-12-17
EP2424507A1 (en) 2012-03-07
AU2010241736A1 (en) 2011-12-22
CA2758738A1 (en) 2010-11-04
AU2010241736B2 (en) 2016-01-28
JP2012525396A (ja) 2012-10-22
EP2424507A4 (en) 2012-10-24
JP2015229678A (ja) 2015-12-21
CN102413817A (zh) 2012-04-11

Similar Documents

Publication Publication Date Title
BRPI1013992A2 (pt) composições e métodos para o tratamento de resistência à insulina e diabetes melito
NO2024044I1 (no) Insulin icodec
BRPI0910282A2 (pt) Composto oxadiazo-antraceno para o tratamento de diabetes
HUE038279T2 (hu) Klotho-béta-agonista antitest cukorbetegség vagy inzulinrezisztencia kezelésében történõ alkalmazásra
BRPI0716134A2 (pt) tratamento de combinaÇço para diabetes mellitus
BRPI1012642A2 (pt) formulação de insulina e método para o tratamento de um indivíduo diabético.
DK2252312T3 (da) Fremgangsmåder til forebyggelse eller behandling af insulinresistens
BRPI0911782A2 (pt) composição de insulina de ação super rápida
FI20096188A0 (fi) Nutrigeneettisiä biomarkkereita lihavuudelle ja tyypin 2 diabetekselle
BRPI1006145A2 (pt) "composição e método para tratamento de diabetes".
BRPI0908416A2 (pt) Seringa para injeção
EP2367541A4 (en) FORMULATION WITH TAXED RELEASE AND ABUSE PROTECTION
EP2409997A4 (en) REDOX-HARDENING COMPOSITION
DK3181134T3 (da) Bifidobakterier til behandling af diabetes og relaterede tilstande
IL205554A (en) An insulin resistance treatment containing melanocortin
BRPI0815760A2 (pt) Composição dermatológica injetável para o tratamento de rugas
BR112012000502A2 (pt) terapia de combinação para o tratamento de diabetes
BRPI0919288A2 (pt) teriapia de combinação para tratamento de diabetes e condições relacionadas.
BRPI0822830A2 (pt) Seringa com mecanismo de desativação
BRPI0906094A2 (pt) composto e método de tratamento de diabetes do tipo ii
BRPI0810525A2 (pt) Composições e métodos para a profilaxia e tratamento de dependência química
BRPI0911083A8 (pt) métodos para o tratamento ou prevenção da diabetes mellitus e outros desequilíbrios metabólicos
BRPI0806964A2 (pt) Combinações de agonístico beta-2-adrenoceptor e benzotiazolona
PL2403605T3 (pl) Kompozycje zawierające przeciwciało specyficzne względem aP2 albo jego fragment do zastosowania w leczeniu cukrzycy, nietolerancji glukozy lub insulinooporności wywołanej otyłością
BR112012006437A2 (pt) composições e métodos para tratamento do diabetes e outros distúrbios

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]